Une approche biochimique du mécanisme d'action de la vasopressine, de l'ocytocine, du vasoactive intestinale peptide et du carbachol au niveau du système nerveux = Vasopressin oxytocin, vasoactive intestinal peptide and carbachol mechanisms of action in the nervous systemAudigier Orleans, Sylvie; Barberis, Claude.1989, 107 p.Thesis

Les récepteurs de l'ocytocine dans le rein de rat en développement = The oxytocin receptors during the post natal development of the rat kidneySchmidt, Anne; Barberis, Claude.1991, 95 p.Thesis

ETUDE DES SITES DE LIAISON DES ANTAGONISTES PEPTIDIQUES LINEAIRES DU RECEPTEUR V1A DE LA VASOPRESSINE PAR UNE APPROCHE DE MARQUAGE COVALENT ET DE MUTAGENESE DIRIGEE = STUDY OF LINEAR PEPTIDIC ANTAGONIST-BINDING SITES OF THE V1A VASOPRESSIN RECEPTOR USING PHOTOAFFINITY LABELING AND SITE-DIRECTED MUTAGENESISPhalipou, Sylvie; Barberis, Claude.1998, 170 p.Thesis

Les canaux calciques des cellules glomérulées de la surrénale de rat: mise en évidence et caractérisation par la technique du patch-clamp = Calcium channels of rat adrenal glomerulosa cells: characterization with the patch-clamp techniqueDurroux, Thierry; Barberis, Claude.1991, 150 p.Thesis

Discovery of thieno[2,3-c]pyridines as potent COT inhibitorsGEORGE, Dawn; FRIEDMAN, Michael; GORDON, Thomas et al.Bioorganic & medicinal chemistry letters (Print). 2008, Vol 18, Num 18, pp 4952-4955, issn 0960-894X, 4 p.Article

Introduction of a cis-prolyl mimic in position 7 of the peptide hormone oxytocin does not result in antagonistic activityWITTELSBERGER, Angela; PATINY, Luc; SLANINOVA, Jirina et al.Journal of medicinal chemistry (Print). 2005, Vol 48, Num 21, pp 6553-6562, issn 0022-2623, 10 p.Article

Design of benzophenone-containing photoactivatable linear vasopressin antagonists : Pharmacological and photoreactive propertiesPONTHIEUX, Sylvie; CABOT, Joëlle; MOUILLAC, Bernard et al.Journal of medicinal chemistry (Print). 2005, Vol 48, Num 9, pp 3379-3388, issn 0022-2623, 10 p.Article

Discovery and development of a new class of potent, selective, orally active oxytocin receptor antagonistsQUATTROPANI, Anna; DORBAIS, Jérome; AYALA, Guidon et al.Journal of medicinal chemistry (Print). 2005, Vol 48, Num 24, pp 7882-7905, issn 0022-2623, 24 p.Article

Design, synthesis and pharmacological characterization of a potent radioiodinated and photoactivatable peptidic oxytocin antagonistCARNAZZI, Eric; AUMELAS, André; MOUILLAC, Bernard et al.Journal of medicinal chemistry (Print). 2001, Vol 44, Num 18, pp 3022-3030, issn 0022-2623Article

2,4-Diaminopyrimidine MK2 inhibitors. Part II: Structure-based inhibitor optimizationHARRIS, Christopher M; ERICSSON, Anna M; JOHNSON, Eric F et al.Bioorganic & medicinal chemistry letters (Print). 2010, Vol 20, Num 1, pp 334-337, issn 0960-894X, 4 p.Article

Presence of functional oxytocin receptors in cultured human myoblastsBRETON, Christophe; HAENGGELI, Christine; BARBERIS, Claude et al.The Journal of clinical endocrinology and metabolism. 2002, Vol 87, Num 3, pp 1415-1418, issn 0021-972XArticle

Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V_1a receptorsTERRILLON, Sonia; LING LING CHENG; STOEV, Stoytcho et al.Journal of medicinal chemistry (Print). 2002, Vol 45, Num 12, pp 2579-2588, issn 0022-2623Article

A ¹³C NMR approach to categorizing potential limitations of α, β-unsaturated carbonyl systems in drug-like moleculesCUSACK, Kevin P; ARNOLD, Lee D; TARCSA, Edit et al.Bioorganic & medicinal chemistry letters (Print). 2004, Vol 14, Num 22, pp 5503-5507, issn 0960-894X, 5 p.Article